Boehringer-Zealand’s obesity drug shows promise in cutting visceral, liver fat
June 8, 2026
Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs inte...